Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + fluorouracil + leucovorin
- Development stage
- Phase 3
- Lead developer
- Michigan State University
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination is used in chemotherapy for treating various cancers, including head and neck squamous cell carcinoma and recurrent head and neck cancer. Cisplatin is a platinum-based antineoplastic drug, fluorouracil (5-FU) is a pyrimidine analog, and leucovorin is a folinic acid derivative that enhances the efficacy of 5-FU by stabilizing its active metabolite. The combination works by inducing DNA damage and inhibiting DNA synthesis.
- Other names
- PFL
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on cisplatin + fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + fluorouracil + leucovorin.